PHIBRO ANIMAL HEALTH CORP

Business Segment(s) · Location · Leased · Footage · Purpose(s)

Animal Health · Buenos Aires, Argentina · Owned · 43,000 · Manufacturing and Administrative

Animal Health · Braganca Paulista, Brazil · Owned · 884,000 · Manufacturing, Sales and Administrative

Animal Health · Guarulhos, Brazil · Owned · 1,236,000 · Manufacturing, Sales, Premixing, Research and Administrative

Animal Health · Heliópolis, Brazil · Owned · 32,000 · Manufacturing, Sales and Administrative

Animal Health · Sligo, Ireland · Owned · 57,000 · Manufacturing and Research

Animal Health · Beit Shemesh, Israel · Leased · 190,000 · Manufacturing, Research and Administrative

Animal Health · Neot Hovav, Israel · Owned/land lease · 140,000 · Manufacturing and Research

Animal Health · Petach Tikva, Israel · Owned · 60,000 · Manufacturing

Animal Health · Sarasota, Florida · Leased · 93,000 · Manufacturing, Sales, Research and Administrative

Animal Health · Chillicothe, Illinois · Owned · 19,000 · Manufacturing

Animal Health · Mendon, Illinois · Owned · 64,000 · Research

Animal Health · St. Paul, Minnesota · Leased · 5,000 · Research

Animal Health · Omaha, Nebraska · Owned · 60,000 · Manufacturing, Sales and Research

Animal Health · State College, Pennsylvania · Owned · 13,000 · Research

Animal Health · Salisbury, Maryland · Leased · 87,000 · Manufacturing

Animal Health · Willow Island, West Virginia · Owned/land lease · 1,220,000 · Manufacturing

Animal Health · Chicago Heights, Illinois · Owned · 215,000 · Manufacturing

Animal Health · Eagle Grove, Iowa · Owned · 112,000 · Manufacturing

Animal Health · Suzhou, China · Owned · 150,000 · Manufacturing

Animal Health · Independence, Missouri · Leased · 145,000 · Warehousing

Animal Health · Medolla, Italy · Leased · 6,000 · Manufacturing

Animal Health and Mineral Nutrition · Quincy, Illinois · Owned · 306,000 · Manufacturing, Sales, Research and Administrative

Mineral Nutrition · Omaha, Nebraska · Owned · 84,000 · Manufacturing

Performance Products · Santa Fe Springs, California · Owned · 108,000 · Manufacturing

Corporate · Teaneck, New Jersey · Leased · 50,000 · Corporate and Administrative

• Phibro Animal Health Holdings, Inc. Delaware⁴
• Phibro Animal Health Holdings, Inc. Chile Limitada Chile⁴
• Phibro Animal Health Limited Ireland⁴
• Phibro Animal Health Ltd . Israel⁴
• Phibro Animal Health Ltd. Canada⁴
• Phibro Animal Health PTY Limited Australia⁴
• Phibro Animal Health S.A. Belgium⁴
• Phibro Animal Health SRL Uruguay⁴
• Phibro Animal Health de Argentina SRL Argentina⁴
• Phibro Animal Health de Republica Dominicana, SRL Dominican Republic⁴
• Phibro Animal Health de Venezuela, C.A. Venezuela⁴
• Phibro Animal Nutrition Ltd. Israel⁴
• Phibro Corporation (M) Sdn. Bhd. Malaysia⁴
• Phibro Corporation Limited Hong Kong⁴
• Phibro Hayvan Sagligi Urunleri Sanayi ve Ticaret A.S Turkey⁴
• Phibro Israel Holdings Ltd. Israel⁴
• Phibro Medolla Manufacturing S.R.L. Italy⁴
• Phibro Saude Animal Internacional Ltda. Brazil⁴
• Phibro Saude e Nutricao Animal Ltda . Brazil⁴
• Phibro Suzhou Manufacturing Co., Ltd. China⁴
• Phibro-Tech, Inc. Delaware⁴
• PhibroWood, LLC Delaware⁴
• Phibrochem, Inc. New Jersey⁴
• Prince Agri Products, Inc. Delaware⁴
• Quimica Real Ltda. Brazil⁴
• Western Magnesium Corp. California⁴
• pHi-Tech Animal Health Technologies Ltd. Israel⁴

• The misuse or extra-label use of our products may harm our reputation or result in financial or other damages.
• The public perception of the safety, quality and efficacy of certain of our animal health products may harm our reputation.
• We are dependent on suppliers having current regulatory approvals, and the failure of those suppliers to maintain these approvals or other challenges in replacing any of those suppliers could affect our supply of materials or affect the distribution or sale of our products.
• The raw materials used by us and our third-party contract manufacturers in the manufacture of our products can be subject to price fluctuations and their availability can be limited.
• Our revenues are dependent on the continued operation of our various manufacturing facilities.
• We could be subject to changes in our tax rates, the adoption of new U.S. or foreign tax legislation or exposure to additional tax liabilities.
• A significant portion of our operations are conducted in foreign jurisdictions and are subject to the economic, political, legal and business environments of the countries in which we do business.
• We are subject to product registration and authorization regulations in many of the jurisdictions in which we operate and/or distribute our products, including the United States and member states of the E.U.
• We have significant assets located outside the United States and a significant portion of our sales and earnings is attributable to operations conducted abroad that may be adversely affected by foreign currency exchange rate fluctuations and other inherent risks.
• We have manufacturing facilities located in Israel and a portion of our net sales and earnings is attributable to products produced and operations conducted in Israel.
• We have manufacturing facilities located in Brazil and a portion of our sales and earnings is attributable to products produced and operations conducted in Brazil.
• Certain of our employees are covered by collective bargaining or other labor agreements.
• The loss of key personnel may disrupt our business and adversely affect our financial results.
• Our R&D relies on evaluations in animals, which may become subject to bans or additional regulations.
• Our operations, properties and subsidiaries are subject to a wide variety of complex and stringent federal, state, local and foreign environmental laws and regulations.
• Our operations or products may impact the environment or cause or contribute to contamination or exposure to hazardous substances.
• We have been and may continue to be subject to claims of injury from direct exposure to certain of our products that constitute or contain hazardous substances and from indirect exposure when such substances are incorporated into other companies’ products.
• We are subject to risks from litigation that may materially impact our operations.
• We are subject to risks that may not be covered by our insurance policies.
• We may fail to achieve the anticipated benefits from the acquisition of certain Zoetis products and assets.
• Adverse U.S. and international economic and market conditions may adversely affect our product sales and business.
• We may not be able to realize the expected benefits of our investments in emerging markets.
• Tariffs, trade protection measures or other modifications of foreign trade policy may harm our food animal product customers and adversely affect our product sales and business.
• Our product approval, R&D, acquisition and licensing efforts may fail to generate new products and product lifecycle developments.
• The actual or purported intellectual property rights of third parties may negatively affect our business.
• If our intellectual property rights are challenged or circumvented, competitors may be able to take advantage of our R&D efforts. We are also dependent upon trade secrets, which in some cases may be difficult to protect.
• We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws or trade control laws, as well as other laws governing our international operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, which could adversely affect our business, financial condition and results of operations.
• Increased regulation or decreased governmental financial support for the raising, processing or consumption of food animals could reduce demand for our animal health products.
• Increased or decreased inventory levels at our channel distributors can lead to fluctuations in our revenues and variations in payment terms extended to our distributors can impact our cash flows.
• We have substantial debt and interest payment requirements that may restrict our future operations and impair our ability to meet our obligations under our indebtedness. Restrictions imposed by our outstanding indebtedness, including the restrictions contained in our Amended 2024 Credit Agreement, may limit our ability to operate our business and to finance our future operations or capital needs or to engage in other business activities.
• We may not be able to generate sufficient cash to service all of our indebtedness and may be forced to take other actions to satisfy our obligations under our indebtedness, which may not be successful.
• We are subject to change of control provisions.
• We use machine learning and artificial intelligence (AI) in our business, and challenges with properly managing its use could result in operational, competitive or reputational harm.
• We depend on sophisticated information technology and infrastructure.
• We may be required to write down goodwill or identifiable intangible assets.
• We may be unable to adequately protect our customers’ privacy or we may fail to comply with privacy laws.
• We may be exposed to information technology system failures, network disruptions and breaches in data security.
• Implementing new business lines or offering new products and services may subject us to additional risks.
• Risks Related to Ownership of Our Class A Common Stock
• Our multiple class structure and the concentration of our voting power with certain of our stockholders will limit your ability to influence corporate matters, and conflicts of interest between certain of our stockholders and us or other investors could arise in the future.
• We are classified as a “controlled company” and, as a result, we qualify for, and intend to rely on, exemptions from certain corporate governance requirements. You will not have the same protections afforded to stockholders of companies that are subject to such requirements.
• Our stock price may be volatile or may decline regardless of our operating performance.
• Our majority stockholder has the ability to control significant corporate activities and our majority stockholder’s interests may not coincide with yours.
• Future sales of our Class A common stock, or the perception in the public markets that these sales may occur, may depress our stock price.
• Anti-takeover provisions in our charter documents and Delaware law might discourage or delay acquisition attempts for us that you might consider favorable.
• Our certificate of incorporation designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
• Provisions of our certificate of incorporation could have the effect of preventing us from having the benefit of certain business opportunities that we would otherwise be entitled to pursue.
• We may not pay cash dividends in the future and, as a result, you may not receive any return on investment unless you are able to sell your Class A common stock for a price greater than your initial investment.
• General Risk Factors
• We face competition in each of our markets from a number of large and small companies, some of which have greater financial, R&D, production and other resources than we have.
• Failure to comply with requirements to design, implement and maintain effective internal controls could have a material adverse effect on our business and stock price.
• As a public company, we are subject to financial and other reporting and corporate governance requirements that may be difficult for us to satisfy and may divert management’s attention from our business.
• We may not be able to expand through acquisitions or successfully integrate the products, services and personnel of acquired businesses.
• We may not successfully implement our business strategies or achieve expected gross margin improvements.